← Back to Search

Iberdomide vs Lenalidomide for Multiple Myeloma

Phase 3
Recruiting
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing two treatments, iberdomide and lenalidomide, to see which one is better at preventing cancer from coming back in patients with newly diagnosed multiple myeloma after a stem cell transplant. These treatments help the immune system fight off cancer cells. Lenalidomide has been used for the treatment of multiple myeloma, showing effectiveness and improving survival outcomes.

Who is the study for?
This trial is for individuals with newly diagnosed symptomatic multiple myeloma who've had 3-6 cycles of specific induction therapies and a stem cell transplant within the last year, achieving at least partial response. It's not for those with progressive disease post-transplant, smoldering or nonsecretory myeloma, central nervous system involvement by MM, or other malignancies in the past 5 years.
What is being tested?
The study compares two maintenance therapies after autologous stem cell transplantation in new multiple myeloma patients: Iberdomide versus Lenalidomide. The goal is to see which one is more effective as a long-term treatment following initial therapy and transplant.
What are the potential side effects?
Potential side effects of Iberdomide and Lenalidomide may include blood disorders like anemia or neutropenia, risk of infections due to low white blood cells, digestive issues such as diarrhea or constipation, fatigue, rash, and possibly increased risk of secondary cancers.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Arm A3: Iberdomide Dose 3Experimental Treatment1 Intervention
Group II: Arm A2: Iberdomide Dose 2Experimental Treatment1 Intervention
Group III: Arm A1: Iberdomide Dose 1Experimental Treatment1 Intervention
Group IV: Arm B: LenalidomideActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Iberdomide
2021
Completed Phase 1
~60

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Multiple Myeloma include immunomodulatory drugs (IMiDs) like iberdomide and lenalidomide, which modulate the immune system to target and destroy cancer cells. Proteasome inhibitors, such as bortezomib, disrupt the protein degradation process in cancer cells, leading to cell death. Monoclonal antibodies, like daratumumab, target specific proteins on the surface of myeloma cells, marking them for destruction by the immune system. These treatments are essential for Multiple Myeloma patients as they offer multiple pathways to attack the cancer, potentially leading to better control of the disease and improved survival rates.

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,692 Previous Clinical Trials
4,096,362 Total Patients Enrolled
91 Trials studying Multiple Myeloma
21,181 Patients Enrolled for Multiple Myeloma

Media Library

Arm A1: Iberdomide Dose 1 Clinical Trial Eligibility Overview. Trial Name: NCT05827016 — Phase 3
Multiple Myeloma Research Study Groups: Arm A1: Iberdomide Dose 1, Arm A2: Iberdomide Dose 2, Arm A3: Iberdomide Dose 3, Arm B: Lenalidomide
Multiple Myeloma Clinical Trial 2023: Arm A1: Iberdomide Dose 1 Highlights & Side Effects. Trial Name: NCT05827016 — Phase 3
Arm A1: Iberdomide Dose 1 2023 Treatment Timeline for Medical Study. Trial Name: NCT05827016 — Phase 3
~811 spots leftby Mar 2029